---
category: listing
circular_id: 3d10d94455f7424a
date: '2025-12-09'
description: Board approval for allocation of 5,657,919 equity shares to 14 anchor
  investors at ₹460 per share, raising ₹260.26 crore for Nephrocare Health Services
  Limited's IPO.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={E30F131E-8855-494B-845E-C6AC3FCDA265}&noticeno=20251209-65&dt=12/09/2025&icount=65&totcount=72&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Anchor investor allocation is a key milestone in IPO process, indicating
  institutional interest. Total allocation of ₹260.26 crore demonstrates strong demand
  from quality investors including mutual funds and insurance companies.
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251209-65&attachedId=f10553e0-bb2a-4d14-a22c-e3291c12260e
processing:
  attempts: 1
  content_hash: e68ccff1b0158e9c
  processed_at: '2025-12-09T18:38:58.651752'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-09T14:53:09+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={E30F131E-8855-494B-845E-C6AC3FCDA265}&noticeno=20251209-65&dt=12/09/2025&icount=65&totcount=72&flag=0
severity: medium
source: bse
stocks:
- NEPHROCARE
tags:
- ipo
- anchor-investors
- nephrocare-health-services
- healthcare
- allocation
- equity-shares
- public-issue
title: Public Issue of Nephrocare Health Services Limited - Allocation to Anchor Investors
---

## Summary

Nephrocare Health Services Limited's board of directors approved the allocation of 5,657,919 equity shares to 14 anchor investors at an allocation price of ₹460 per share (face value ₹2, premium ₹458) on December 9, 2025. The total amount raised from anchor investors is ₹260.26 crore. The allocation includes significant participation from domestic mutual funds (45.65% of anchor portion through 6 schemes from 5 mutual funds) and institutional investors.

## Key Points

- Total anchor allocation: 5,657,919 equity shares at ₹460 per share
- Total funds raised from anchors: ₹2,602,642,740 (₹260.26 crore)
- Face value: ₹2 per share, Share premium: ₹458 per share
- 14 anchor investors participated in the allocation
- Domestic mutual funds received 2,582,944 shares (45.65% of anchor portion)
- Life insurance companies and pension funds received 434,815 shares (7.69% of anchor portion)
- Book Running Lead Managers: ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited, and Nomura Financial Advisory and Securities (India) Private Limited

## Anchor Investor Details

**Top Allocations:**
- SBI Healthcare Opportunities Fund: 760,896 shares (13.45%) - ₹35.00 crore
- DSP Healthcare Fund: 619,584 shares (10.95%) - ₹28.50 crore
- ICICI Prudential Pharma Healthcare and Diagnostics Fund: 543,488 shares (9.61%) - ₹25.00 crore
- Fidelity Funds - Pacific Fund: 492,288 shares (8.70%) - ₹22.65 crore

**Mutual Fund Participation:**
- 5 domestic mutual funds participated through 6 schemes
- Total allocation to mutual funds: 2,582,944 shares for ₹118.82 crore
- Healthcare-focused funds showed strong interest (SBI Healthcare, ICICI Prudential Pharma Healthcare, DSP Healthcare)

**Other Institutional Investors:**
- Foreign funds: Fidelity, NEF, Eastspring Investments, Polar Capital, Manulife
- Insurance companies: SBI Life, HDFC Life
- Prudential Assurance Company Limited

## Regulatory Changes

No regulatory changes announced. This is a standard anchor investor allocation disclosure as per SEBI IPO guidelines.

## Compliance Requirements

- Anchor investor allocation finalized in consultation with Book Running Lead Managers
- Allocation disclosed to stock exchanges (BSE and NSE) as required
- Minimum 45.65% allocation to domestic mutual funds meets regulatory requirements for anchor portion
- Insurance company allocation at 7.69% within prescribed limits

## Important Dates

- **December 9, 2025**: Board meeting date and anchor investor allocation date
- IPO opening and closing dates not specified in this circular
- Lock-in period for anchor investors as per SEBI regulations (typically 30-90 days depending on listing gains)

## Impact Assessment

**Market Impact:**
- Strong institutional interest signals confidence in Nephrocare's business model and healthcare sector prospects
- Anchor book oversubscription likely, given quality of investors
- Healthcare sector focus evident from participation of specialized healthcare funds

**Company Impact:**
- Successful anchor allocation is positive indicator for main IPO subscription
- Quality anchor investors (SBI MF, ICICI Prudential, DSP, Fidelity) add credibility
- Price discovery at ₹460 per share provides benchmark for retail/institutional bidding

**Investor Considerations:**
- Anchor allocation represents institutional validation of valuation
- Healthcare services sector exposure through nephrology/dialysis services
- Retail investors should review final prospectus and price band for main IPO